Decreased Libido in Perimenopause and Menopause

What Decreased Libido Feels Like

Common patterns:

• Reduced spontaneous desire — fewer "just thinking about it" moments
• Less response to usual triggers — what used to spark desire now doesn't
• Reduced pleasure or sensation during sex
• Avoiding intimate situations — to avoid disappointment, pain, or pressure
• A sense of loss or grief about the change
• Distress in the relationship — partner concerns, mismatched libido
• Difficulty separating "low desire" from "low arousal" — they often coexist
• Sometimes coexists with painful sex which creates a self-reinforcing avoidance pattern

What it usually does NOT involve (suggests another framing):

• A sudden or major change in sexual desire or arousal — especially after a medication change, new illness, depression, pelvic pain, or relationship stress → deserves a focused medical review
• Distress only from partner expectations, not personal experience → relationship/communication focus
• Recent onset after starting a medication → medication-induced

Why Libido Decreases in Menopause

Decreased libido in midlife is rarely caused by one thing — it's almost always multifactorial. The most effective treatment usually addresses several contributors simultaneously, not just hormones.

A critical clinical point — if sex hurts, desire predictably decreases. Treating vaginal dryness and painful sex often restores desire substantially without any direct desire treatment. Always evaluate for and treat GSM before concluding that low libido is "psychological" or hormonal-only.

Testosterone in women is produced by the ovaries and adrenals ²; levels gradually decline with age, with an additional drop after natural or surgical menopause. The relationship between testosterone level and desire is not linear, but physiologic-dose testosterone replacement can help selected women — particularly those with documented low androgen status and hypoactive sexual desire disorder. This is part of JumpstartMD's BHRT toolkit when clinically indicated.

Is This Normal? When to See a Doctor

Some change in libido during the menopause transition is common. Worth seeing a clinician if:

• Decreased desire is causing distress
• It's affecting your relationship
• Painful sex is contributing
• You suspect medication-induced changes
• You want to explore treatment options

The clinical concept of Hypoactive Sexual Desire Disorder (HSDD) ¹ describes persistent or recurrent absent or reduced sexual desire causing distress. HSDD has FDA-approved treatments for premenopausal women (flibanserin, bremelanotide); use in postmenopausal women is off-label. You may also hear related terms such as female sexual interest/arousal disorder (FSIAD) — clinicians use somewhat different terminology depending on the diagnostic framework. Distinguishing HSDD from situational, age-related, or medication-induced low desire matters for treatment.

Clinical Red Flags — Other Causes to Consider

• Sudden onset of low libido after a medication change — likely medication-induced
• Profound fatigue, weight changes, cold intolerance with low libido — possible thyroid disease
• Significant depression with low libido — depression treatment may be primary
• Pain during sex — needs evaluation and early treatment alongside other contributors
• Other medical contributors — uncontrolled diabetes, chronic pain, major medical illness, substance use, and rarely elevated prolactin or other endocrine disorders
• If intimacy feels unsafe, pressured, or coercive — this is not a libido problem and deserves support and protection
• Hormonal symptoms suggesting POI in younger women — needs evaluation
• History of sexual trauma — may need specialized care
• Severe relationship distress — may need couples therapy primarily

What You Can Do About It

The most important step: identify what's actually contributing.

Address painful sex early — alongside other contributors

If sex hurts, treating the pain often restores desire substantially. See Painful Sex (Dyspareunia) in Perimenopause and Menopause for full treatment options. Vaginal estrogen, prasterone (Intrarosa), ospemifene (Osphena), and lubricants all address the friction-pain component that drives avoidance. If pain is burning, entry-related, or associated with pelvic floor tension, pelvic floor physical therapy may also help. Mood, sleep, medications, and relationship factors usually need to be addressed in parallel rather than sequentially.

Address mood and sleep

Depression, anxiety, and chronic sleep loss are major libido drivers. Treating these often improves desire as a side effect.

Review medications

SSRIs are the most common medication cause. If on an SSRI for depression or anxiety, switching to bupropion (less libido effect) or adding bupropion may help. Don't stop SSRIs without medical guidance.

Hormone therapy / BHRT

Bioidentical hormone replacement therapy (BHRT) — typically FDA-approved bioidentical estradiol paired with oral micronized progesterone in women with a uterus — may improve sexual function indirectly, especially by reducing vaginal dryness/pain, hot flashes, and sleep disruption.

Its direct effect on sexual desire is less consistent.

Progesterone is included as a uterine-protection measure for women with a uterus on systemic estrogen (it can occasionally cause drowsiness or temporary mood shifts in some women).

Note on safety: systemic estrogen is not appropriate for all women — particularly those with a history of hormone-receptor-positive breast cancer, active cardiovascular disease or stroke, blood clot history, active liver disease, or undiagnosed vaginal bleeding.

Low-dose vaginal estrogen has much lower systemic absorption than systemic hormone therapy and is often an option even when systemic estrogen is not — but for breast cancer survivors, especially those taking aromatase inhibitors, the decision should be made in shared discussion with the patient's oncology team.

Testosterone supplementation (off-label in the US for women; approved in some other countries for HSDD):

• If used, transdermal testosterone (cream or gel) at low doses tailored for women — typically prescribed for postmenopausal women with distressing low desire/HSDD after other contributors are addressed
• Because there is no FDA-approved female testosterone product in the US, prescriptions typically use a fraction of an FDA-approved male product (carefully calculated) or compounded formulations from accredited compounding pharmacies. Patients should know which approach their clinician uses
• Evidence is strongest for women with HSDD and includes both surgically and naturally postmenopausal women
• Requires baseline and follow-up testosterone testing to keep levels in the physiologic female range, plus clinical monitoring for androgenic adverse effects (acne, hirsutism, scalp hair loss, voice change, mood effects)
• A blood testosterone level alone does not diagnose the cause of low libido, and a "normal" result does not rule out distressing low desire. Treatment decisions are based on symptoms, contributors, and risk–benefit discussion — not lab numbers alone
• Not appropriate for all women; specialist guidance valuable

Specific HSDD treatments

• Flibanserin (Addyi) ⁶ — daily oral medication approved for acquired, generalized HSDD in premenopausal women. Benefits are modest. Can cause sleepiness, dizziness, low blood pressure, and risk of fainting; has important interactions with alcohol and CYP3A4-inhibiting medications, so careful counseling is needed
• Bremelanotide (Vyleesi) ⁷ — on-demand self-injection approved for acquired, generalized HSDD in premenopausal women. Commonly causes nausea and can transiently raise blood pressure; not appropriate for patients with uncontrolled hypertension or significant cardiovascular disease
• Both medications are sometimes used off-label in postmenopausal patients after individualized risk-benefit discussion

Lifestyle and relational

• Couples therapy or sex therapy — particularly valuable for relational impact, communication, and adapting expectations
• Mindfulness-based approaches — evidence-based for sexual function
• Make time and space for intimacy — practical scheduling sometimes helps
• Communication with partner about what helps, what hurts, what to try
• Exercise — improves body image, mood, energy, and direct sexual response
• Limit alcohol — initially disinhibits but impairs sexual function

Get Started with JumpstartMD

Decreased libido in midlife isn't something to accept as inevitable.

JumpstartMD's perimenopause and menopause care is part of our broader Total Health Optimization approach — a medically-supervised bioidentical hormone therapy program delivered by an expert team of licensed clinicians (under physician oversight), supported by lifestyle coaching for the behavioral side of care. Treatment balances five key hormones — estrogen, progesterone, DHEA, testosterone, and thyroid — through pills, creams, patches, injections, or subcutaneous pellet therapy (in-person visits only).

The program follows a structured pathway: a phone connection with our team, an online health questionnaire, comprehensive hormone labs at Quest Laboratories, a clinical consultation to review results, a personalized treatment plan, and regular follow-ups to fine-tune dosing as your body responds. Care is delivered in-person at our 14 California clinics or online from anywhere in California. When weight or metabolic health is contributing to your symptoms, BHRT is coordinated with our medical weight loss program in the same care plan.

Membership benefits include comprehensive lab testing, ongoing support and monitoring, exclusive member pricing on products, and concierge medical insurance claims assistance for PPO out-of-network plans (FSA/HSA accepted).

Ready to talk?

Book FREE Consultation

Share your details and a JumpstartMD team member will reach out shortly. Or call 408.478.3496 for your free, no-obligation consultation.